Youn-HeeKimMD

PubMed

• 6 citations
  Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative D...
  Joan Guitart, Aaron R Mangold, Maria Estela Martinez-Escala, Christina J Walker, Nneka I Comfere, Mellissa Pulitzer, Kerri E Rieger, Carlos A Torres-Cabala, Laura B Pi...> ;JAMA Dermatology. 2022 Oct 1
• 3 citations
  What factors guide treatment selection in mycosis fungoides and Sezary syndrome?
  Youn H Kim> ;Hematology. American Society of Hematology. Education Program. 2021 Dec 10
• 45 citations
  Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
  Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren C. Pinter-Brown, Francine M. Foss, Larisa J. Geskin, Lawrence H. Schwartz, Steven M. Horwitz, Joan Guitart, John ...> ;Blood. 2021 Nov 10
• 33 citations
  Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
  Kelsey E. Hirotsu, Tatiana M. Neal, Michael S. Khodadoust, Jennifer Y. Wang, Kerri E. Rieger, Jenna Strelo, E. Hong, Youn H. Kim, Bernice Y. Kwong> ;JAMA Dermatology. 2021 Jun 1
• 21 citations
  Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
  Reinhard Dummer, Henry Miles Prince, Sean Whittaker, Steven M. Horwitz, Youn H. Kim, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Era...> ;European Journal of Cancer. 2020 Jul 1
• Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin.
  Kheterpal, M. K.,Dai, J.,Geller, S.,Pulitzer, M.,Ni, A.,Myskowski, P. L.,Moskowitz, A.,Kim, J.,Hong, E. K.,Fong, S.,Hoppe, R. T.,Kim, Y. H.,Horwitz, S. M.> ;J. Am. Acad. Dermatol.. 2019 Feb 01
• HASH(0x28a0470)
  Torrey, H.,Khodadoust, M.,Tran, L.,Baum, D.,Defusco, A.,Kim, Y. H.,Faustman, D. L.> ;Leukemia. 2018 Oct 26
• 341 citations
  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
  Mavoric Investigators> ;The Lancet. Oncology. 2018 Sep 1
• 15 citations
  Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma
  Ziba Rahbar, Shufeng Li, Mahkam Tavallaee, Roberto A. Novoa, Jinah Kim, Youn H. Kim> ;The Journal of Investigative Dermatology. 2018 May 1
• The Optimal Regimen of Brentuximab Vedotin for CD30+ Cutaneous Lymphoma: Are We There Yet?
  S Horwitz, P L Myskowski, Y H Kim> ;The British Journal of Dermatology. 2017 Oct 13
• 113 citations
  Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors
  Kun Qu, Lisa C. Zaba, Ansuman T. Satpathy, Paul G. Giresi, Rui Li, Yonghao Jin, Randall Armstrong, Chen Jin, Nathalie Schmitt, Ziba Rahbar, Hideki Ueno, William J. Gre...> ;Cancer Cell. 2017 Jul 10
• Paediatric Primary Cutaneous Marginal Zone B-cell Lymphoma: Does It Differ from Its Adult Counterpart?
  M Tavallaee, J Kim, R T Hoppe, L Million, Y H Kim> ;The British Journal of Dermatology. 2016 Aug 09
• 194 citations
  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collabor...
  Youn H. Kim, Mahkam Tavallaee, Uma Sundram, Katrin A. Salva, Gary S. Wood, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T. Hoppe, Annie...> ;Journal of Clinical Oncology. 2015 Jul 20
• 33 citations
  Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.
  Youn H. Kim, Marie-France Demierre, Ellen J. Kim, Adam Lerner, Alain H. Rook, Madeleine Duvic, Tadeusz Robak, Alexey Samtsov, William McCulloch, Suephy C. Chen, Joel W...> ;Leukemia & Lymphoma. 2013 Feb 1
• 155 citations
  In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
  Youn H. Kim, Dita Gratzinger, Cameron Harrison, Joshua Brody, Debra K. Czerwinski, Weiyun Z. Ai, Anjali V. Morales, Farah Abdulla, Leon Xing, Daniel Navi, Robert Tibsh...> ;Blood. 2012 Jan 12
• 71 citations
  Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
  Youn H. Kim, Michael Girardi, Madeleine Duvic, Timothy M. Kuzel, Brian K. Link, Lauren Pinter-Brown, Alain H. Rook> ;Journal of the American Academy of Dermatology. 2010 Dec 1
• Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.
  Kim, Y. H.,Kwei, K. A.,Girard, L.,Salari, K.,Kao, J.,Pacyna-Gengelbach, M.,Wang, P.,Hernandez-Boussard, T.,Gazdar, A. F.,Petersen, I.,Minna, J. D.,Pollack, J. R.> ;Oncogene. 2009 Dec 08
• 127 citations
  Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
  Youn H. Kim, Madeleine Duvic, Erik Obitz, Robert Gniadecki, Lars Iversen, Anders Österborg, Sean Whittaker, Timothy M Illidge, Thomas Schwarz, Roland Kaufmann, Kevin D...> ;Blood. 2007 Jun 1
• 244 citations
  TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymph...
  Youn H. Kim, Rein Willemze, Nicola Pimpinelli, Sean Whittaker, Elise A. Olsen, Annamari Ranki, Reinhard Dummer, Richard T. Hoppe> ;Blood. 2007 Jul 15
• 29 citations
  Management with topical nitrogen mustard in mycosis fungoides.
  Youn H. Kim> ;Dermatologic Therapy. 2003 Dec 1
• 126 citations
  Topical Nitrogen Mustard in the Management of Mycosis Fungoides: Update of the Stanford Experience
  Youn H. Kim, Gina Martinez, Anna Varghese, Richard T. Hoppe> ;Archives of Dermatology. 2003 Feb 1
• Join now to see all

Journal Articles

• Targeted Killing of TNFR2-Expressing Tumor Cells and Tregs by TNFR2 Antagonistic Antibodies in Advanced Sézary Syndrome  
  D L Faustman, Y H Kim, M Khodadoust, Nature

Abstracts/Posters

• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Youn H. Kim, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019